Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation (NASDAQ: RGEN) is a global life sciences company specializing in the development, production, and commercialization of innovative bioprocessing technologies and systems that enhance the efficiency of biological drug manufacturing. Headquartered in Waltham, Massachusetts, the company operates additional manufacturing facilities in Sweden, Estonia, France, Germany, Ireland, the Netherlands, and the United States.
Repligen is renowned for its high-quality bioprocessing products, which are essential in the production of biological drugs. The company's product portfolio includes Protein A, a critical reagent used in the manufacturing of monoclonal antibody-based therapeutics, and several growth factor products that boost cell culture productivity in biomanufacturing. Additionally, Repligen offers OPUS™ (Open Platform User Specified) single-use chromatography columns, which are pivotal in the biologics purification process.
The company serves a diverse customer base that includes major life sciences and biopharmaceutical companies, as well as contract development and manufacturing organizations (CDMOs) worldwide. Repligen markets its products globally through a direct sales organization in the U.S., Europe, and Asia, complemented by strategic partnerships in select regions. North America remains the primary market, contributing the majority of the company's revenue.
Recent achievements include the acquisition of Metenova AB, a leading innovator in magnetic mixing technologies, to expand its Fluid Management portfolio. Despite challenges in the bioprocessing market, Repligen continues to exhibit resilience with steady revenue growth, particularly in its Analytics and Chromatography franchises.
Financially, Repligen reported second quarter revenues of $159.2 million in 2023 and has adjusted its full-year revenue guidance to a range of $635-$665 million. The company remains optimistic about overcoming current market headwinds, with a growing pipeline of opportunities expected to bolster orders in the fourth quarter.
Overall, Repligen's commitment to bioprocessing technology leadership and continuous innovation positions it as a significant player in the life sciences industry, driving advancements that support the development of life-saving biological drugs.
Repligen Corporation (NASDAQ:RGEN) will announce its first quarter 2023 financial results on May 2, 2023, before the market opens. A conference call is scheduled for 8:30 a.m. ET to discuss business updates and financial results for the quarter ending March 31, 2023. Investors can join the call by dialing (844) 274-3999 (U.S.) or (412) 317-5607 (international) without a passcode. A webcast will also be available on the Company’s Investor Relations page. Repligen specializes in bioprocessing technologies for biopharmaceutical manufacturing.
Repligen Corporation (NASDAQ:RGEN) announced its participation in the KeyBanc Life Science and MedTech Investor Forum on March 21-22, 2023. CEO Tony J. Hunt will lead an analyst-led discussion on March 21 at 1:30 p.m. EDT. A live webcast of the presentation will be available on the Company's Investor Relations website and will be accessible for replay after the event. Repligen specializes in bioprocessing technologies, aiming to improve the manufacturing efficiency of biological drugs for biopharmaceutical developers and contract organizations globally. The company operates in various locations, primarily within the U.S., and has a strong presence in multiple European countries.
Repligen Corporation (NASDAQ:RGEN) reported strong financial results for the fourth quarter and full year 2022. Fourth quarter revenue reached $186.8 million, marking 4% organic growth year-over-year, while full-year revenue totaled $801.5 million, a 22% organic growth. The base business demonstrated impressive organic growth of 35% in Q4 and 39% for the year. Despite these achievements, gross profit decreased in Q4 by 9%, impacted by declining COVID-related product revenues and increased costs. Looking ahead, Repligen expects 2023 total revenue between $760-$800 million, anticipating a reduction in COVID-related revenue and gross margin decline to 52.5%-53.5%.
FAQ
What is the current stock price of Repligen (RGEN)?
What is the market cap of Repligen (RGEN)?
What does Repligen Corporation specialize in?
Where is Repligen's headquarters located?
What are some key products offered by Repligen?
Who are Repligen's primary customers?
How does Repligen market its products?
What recent acquisition has Repligen made?
What was Repligen's revenue for the second quarter of 2023?
What is Repligen's revenue guidance for the year 2023?
Which regions contribute the most to Repligen's revenue?
What is Repligen's focus area?
